Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated:  8/31/2017
2373
mi
from 98109
Philadelphia, PA
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated: 8/31/2017
Fox Chase Cancer Center - Philadelphia
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated:  8/31/2017
1892
mi
from 98109
Houston, TX
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated: 8/31/2017
M. D. Anderson Cancer Center at University of Texas
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated:  8/31/2017
2284
mi
from 98109
Charlottesville, VA
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated: 8/31/2017
University of Virginia Cancer Center
2284
mi
from 98109
Charlottesville, VA
Click here to add this to my saved trials
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Status: Enrolling
Updated:  9/5/2017
2135
mi
from 98109
Pittsburgh, PA
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Status: Enrolling
Updated: 9/5/2017
UPMC Cancer Centers
2135
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
2072
mi
from 98109
Birmingham, AL
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
2148
mi
from 98109
Mobile, AL
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
2148
mi
from 98109
Mobile, AL
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
1053
mi
from 98109
La Jolla, CA
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1053
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
960
mi
from 98109
Los Angeles, CA
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
960
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
680
mi
from 98109
San Francisco, CA
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
655
mi
from 98109
Vallejo, CA
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
655
mi
from 98109
Vallejo, CA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
2549
mi
from 98109
Orlando, FL
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
2549
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
1867
mi
from 98109
Indianapolis, IN
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
1905
mi
from 98109
Ann Arbor, MI
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1905
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
2393
mi
from 98109
Lebanon, NH
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
2393
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
2400
mi
from 98109
New York, NY
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
7755
mi
from 98109
Westmead,
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
7755
mi
from 98109
Westmead,
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1128
mi
from 98109
Chandler, AZ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Ironwood Cancer and Research Centers
1128
mi
from 98109
Chandler, AZ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1115
mi
from 98109
Phoenix, AZ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Omni Dermatology
1115
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1106
mi
from 98109
Phoenix, AZ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Alliance Dermatology & MOHS Center, PC
1106
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1220
mi
from 98109
Tucson, AZ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Arizona Cancer Center
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1643
mi
from 98109
Fayetteville, AR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Highlands Oncology Group, P.A.
1643
mi
from 98109
Fayetteville, AR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1759
mi
from 98109
Hot Springs, AR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Burke Pharmaceutical Research
1759
mi
from 98109
Hot Springs, AR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1780
mi
from 98109
Little Rock, AR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Arkansas for Medical Sciences
1780
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
959
mi
from 98109
Duarte, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
City of Hope
959
mi
from 98109
Duarte, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
962
mi
from 98109
Los Angeles, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
The Angeles Clinic & Research Institute
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
941
mi
from 98109
Oxnard, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Ventura County Hematology Oncology Specialists
941
mi
from 98109
Oxnard, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
627
mi
from 98109
Sacramento, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Sutter Cancer Center
627
mi
from 98109
Sacramento, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
681
mi
from 98109
San Francisco, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Northern California Melanoma Center, St. Mary's Medical Center
681
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1013
mi
from 98109
Temecula, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Advanced Dermatology and Skin Cancer Specialists
1013
mi
from 98109
Temecula, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1026
mi
from 98109
Aurora, CO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Anschutz Cancer Pavilion
1026
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
mi
from 98109
Boca Raton, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Skin Care research Inc
mi
from 98109
Boca Raton, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
mi
from 98109
Jacksonville, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Cancer Specialists of North Florida
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2732
mi
from 98109
Miami Beach, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Mount Sinai Medical Center
2732
mi
from 98109
Miami Beach, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2720
mi
from 98109
Miami Lakes, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Lake Research LLC
2720
mi
from 98109
Miami Lakes, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2547
mi
from 98109
Orlando, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
M.D. Anderson Cancer Center at Orlando
2547
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2526
mi
from 98109
Ormond Beach, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Ameriderm Research
2526
mi
from 98109
Ormond Beach, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1721
mi
from 98109
Niles, IL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Oncology Specialists, SC (OSSC)
1721
mi
from 98109
Niles, IL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1860
mi
from 98109
Indianapolis, IN
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Investigative Clinical Research of Indiana
1860
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1557
mi
from 98109
Iowa City, IA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Iowa Hospitals and Clinics
1557
mi
from 98109
Iowa City, IA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2010
mi
from 98109
Lexington, KY
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Central Kentucky Research Associates, Inc.
2010
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1938
mi
from 98109
Louisville, KY
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Louisville
1938
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1954
mi
from 98109
Lake Charles, LA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Clinical Research Facility
1954
mi
from 98109
Lake Charles, LA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2332
mi
from 98109
Baltimore, MD
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Harry and Jeanette Weinberg Cancer Institute at Franklin Square
2332
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1921
mi
from 98109
Southfield, MI
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Providence Cancer Institute
1921
mi
from 98109
Southfield, MI
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
mi
from 98109
Minneapolis, MN
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Minnesota Masonic Cancer Institute
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1450
mi
from 98109
Rochester, MN
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Mayo Clinic Cancer Center, Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
1507
mi
from 98109
Kansas City, MO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
The Center for Pharmaceutical Research, P.C.
1507
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2392
mi
from 98109
Lebanon, NH
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2427
mi
from 98109
Greenville, NC
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
E. Carolina University; Brody School of Medicine
2427
mi
from 98109
Greenville, NC
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
2275
mi
from 98109
Winston-Salem, NC
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Wake Forest University School of Medicine, Comprehensive Cancer Center
2275
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials